Is There a Correlation Between DMD and Visual Outcomes After RRD Repair?

Is There a Correlation Between DMD and Visual Outcomes After RRD Repair

There is considerable debate regarding the allowable duration of time prior to surgical intervention for macula-involving retinal detachments. Many prior studies recommend surgery within one week of detachment, with a range of 2 days to 2 weeks published in the literature. The authors argue that these studies may be limited by sample size and their retrospective nature. They sought to find a better understanding of the impact of duration of macular detachment (DMD) on visual prognosis.

This prospective observational cohort study sought to determine a correlation between DMD and visual outcomes after rhegmatogenous retinal detachment (RRD) repair. A total of 719 eyes with macula-off RRD performed between February 2016 and March 2017 queried from the Japan-Retinal Detachment Registry were included. Notably, demographics data for all patients in this registry were prospectively registered prior to surgical intervention. Outcomes were compared 6 months postoperatively, with best corrected visual acuity (BCVA) at 6 months as a primary endpoint. Five comparisons were performed: surgery within N days from the onset of macular detachment versus surgery after N+1 days from the onset of macular detachment (N= 2 to 5 days). Eyes with prior ocular surgery other than cataract surgery, pars plana vitrectomy, and surgery for prior RD were excluded.

Six months after surgery, BCVA was significantly better in patients whose retinal detachment repair occurred within 2 days of macular detachment onset as compared to those whose macular detachment lasted 3 days or longer (P = 9.1 × 10–7). Similarly, if the DMD was 3 days or less the BCVA was statistically significantly better in comparison to 4 days or more (P = 1.6 × 10–3). Comparisons of surgeries performed within 4 days of the onset of macular detachment versus those performed after 5 days and those performed within 5 days of the onset of macular detachment versus those performed after 6 days also revealed better acuity with earlier surgery, but the differences were not statistically significant.

The authors discuss that their findings are compatible with previous retrospective studies, as well as RD models that show that cone cells initiate apoptosis within 1 day of RD and peak at approximately 3 days. They argue that their large sample size, the comprehensive data from the Japan-Retinal Detachment Registry, and their method of statistical analysis to adjust for background imbalances (such as influences of institutional preferences, preoperative visual function, and the nature of the RD) makes their study unique in comparison to retrospective reviews.

Limitations of this study include that DMD was based on the patient's complaint and, therefore, is an imprecise measure that may have introduced bias. In addition, patients with a prior history of vitrectomy for any reason (including macular pathology and previous macular RDs) were included and may have affected the results, as prior macular status was not discussed. Lastly, data were only recorded up to 6 months postoperatively, and true final visual acuity is unknown.

In conclusion, the authors note that their findings support RD repair within 2 to 3 days of macular detachment yields the best BCVA at 6 months, while the timing of surgical intervention did not significantly impact visual prognosis with DMD between 4 to 6 days. The authors encourage consideration of earlier surgical treatment of macula-involving RDs when social circumstances, including access to OR time and resources, allow.

Details
  • Overview

    May 2023: VBS Literature Update

    Miyake M, Nakao SY, Morino K, et al. Effect of duration of macular detachment on visual prognosis after surgery for macula-off retinal detachment: Japan-Retinal Detachment Registry. Ophthalmol Retina. 2023;7(5):375-382.

    Abstract by Mariam Mathai, MD

  • Learning Objectives

    Upon completion of this activity, the participant should be able to:

    • Discuss how duration of macular detachment and time to surgery may affect visual outcomes in patients with macula-involving rhegmatogenous retinal detachments
    • Accreditation

       Provided by Evolve Medical Education

      Accreditation Statement
      This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Evolve Medical Education, LLC and Vit Buckle Society.  Evolve Medical Education, LLC is accredited by the ACCME to provide continuing medical education for physicians.

      Credit Designation Statement
      Evolve Medical Education LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    • Participation Method

      In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.

    • Faculty and Disclosures

      Mariam Mathai, MD

      Mariam Mathai, MD

      The Retina Group of Washington
      Medstar Georgetown Department of Ophthalmology
      Washington, DC


      DISCLOSURE POLICY
      It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.

      The following faculty/staff members have the following financial relationships with ineligible companies.

      Mariam Mathai, MD, has no financial relationships or affiliations with ineligible companies.

      The Evolve staff and planners have no financial relationships with ineligible companies.
      Nisha Mukherjee, MD, peer reviewer, has no financial relationships with ineligible companies.

    • Disclaimer

      OFF-LABEL STATEMENT
      This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

      DISCLAIMER
      The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Vit Buckle Society.

      This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

    • System Requirements

      • Supported Browsers (2 most recent versions):
        • Google Chrome for Windows, Mac OS, iOS, and Android
        • Apple Safari for Mac OS and iOS
        • Mozilla Firefox for Windows, Mac OS, iOS, and Android
        • Microsoft Edge for Windows
      • Recommended Internet Speed: 5Mbps+

    • Publication Dates

      Expiration Date:

    0.25 credits
    Completing the pre-test is required to access this content.
    Completing the pre-survey is required to view this content.

    Ready to Claim Your Credits?

    You have attempts to pass this post-test. Take your time and review carefully before submitting.

    Good luck!

    Register

    We're glad to see you're enjoying Evolve Medical Education…
    but how about a more personalized experience?

    Register for free